O	0	8	Efficacy
O	9	11	of
B-intervention	12	23	anastrozole
O	24	29	after
O	30	39	tamoxifen
O	40	42	in
O	43	48	early
O	49	55	breast
O	56	62	cancer
O	63	71	patients
O	72	76	with
O	77	89	chemotherapy
O	89	90	-
O	90	97	induced
O	98	105	ovarian
O	106	114	function
O	115	122	failure
O	122	123	.

O	124	127	The
O	128	132	DATA
O	133	138	study
O	139	140	(
O	140	151	NCT00301457
O	151	152	)
O	153	161	compared
O	162	163	6
O	164	167	and
O	168	169	3
O	170	175	years
O	176	178	of
O	179	190	anastrozole
O	191	193	in
B-eligibility	194	208	postmenopausal
I-eligibility	209	214	women
I-eligibility	215	219	with
I-eligibility	220	227	hormone
I-eligibility	228	236	receptor
I-eligibility	236	237	-
I-eligibility	237	245	positive
I-eligibility	246	251	early
I-eligibility	252	258	breast
I-eligibility	259	265	cancer
I-eligibility	266	271	after
I-eligibility	272	273	2
I-eligibility	273	274	-
I-eligibility	274	275	3
I-eligibility	276	281	years
I-eligibility	282	284	of
I-eligibility	285	294	tamoxifen
O	294	295	.

B-eligibility	296	304	Patients
I-eligibility	305	309	with
I-eligibility	310	322	chemotherapy
I-eligibility	322	323	-
I-eligibility	323	330	induced
I-eligibility	331	338	ovarian
I-eligibility	339	347	function
I-eligibility	348	355	failure
I-eligibility	356	357	(
I-eligibility	357	362	CIOFF
I-eligibility	362	363	)
O	364	368	were
O	369	373	also
O	374	382	eligible
O	382	383	,
O	384	387	but
O	388	393	could
O	394	396	be
O	397	399	at
O	400	404	risk
O	405	407	of
O	408	415	ovarian
O	416	424	function
O	425	433	recovery
O	434	435	(
O	435	438	OFR
O	438	439	)
O	439	440	.

O	441	444	The
O	445	452	current
O	453	461	analysis
O	462	470	compared
O	471	474	the
O	475	483	survival
O	484	486	of
O	487	492	women
O	493	497	with
O	498	503	CIOFF
O	504	508	with
O	509	519	definitely
O	520	534	postmenopausal
O	535	540	women
O	541	544	and
O	545	553	examined
O	554	557	the
O	558	567	influence
O	568	570	of
O	571	574	OFR
O	575	577	on
O	578	586	survival
O	586	587	.

O	588	597	Therefore
O	597	598	,
O	599	601	we
O	602	610	selected
O	611	619	patients
O	620	624	from
O	625	628	the
O	629	633	DATA
O	634	639	study
O	640	644	aged
B-age	645	647	45
I-age	647	648	-
I-age	648	650	57
I-age	651	656	years
O	657	659	at
O	660	673	randomization
O	674	677	who
O	678	681	had
O	682	690	received
O	691	692	(
O	692	695	neo
O	695	696	)
O	696	704	adjuvant
O	705	717	chemotherapy
O	717	718	.

O	719	723	They
O	724	728	were
O	729	739	classified
O	740	742	by
O	743	756	reversibility
O	757	759	of
O	760	774	postmenopausal
O	775	781	status
O	781	782	:
O	783	791	possibly
O	792	802	reversible
O	803	805	in
O	806	810	case
O	811	813	of
O	814	819	CIOFF
O	820	821	(
O	821	822	n
O	823	824	=
B-total-participants	825	828	395
O	828	829	)
O	830	836	versus
O	837	847	definitely
O	848	862	postmenopausal
O	863	864	(
O	864	865	n
O	866	867	=
B-total-participants	868	871	261
O	871	872	)
O	872	873	.

O	874	877	The
O	878	884	former
O	885	889	were
O	890	899	monitored
O	900	902	by
O	903	905	E2
O	906	918	measurements
O	919	922	for
O	923	926	OFR
O	926	927	.

O	928	931	The
O	932	942	occurrence
O	943	945	of
O	946	949	OFR
O	950	953	was
O	954	966	incorporated
O	967	969	as
O	970	971	a
O	972	976	time
O	976	977	-
O	977	986	dependent
O	987	996	covariate
O	997	999	in
O	1000	1001	a
O	1002	1005	Cox
O	1005	1006	-
O	1006	1016	regression
O	1017	1022	model
O	1023	1026	for
O	1027	1038	calculating
O	1039	1042	the
O	1043	1049	hazard
O	1050	1055	ratio
O	1056	1057	(
O	1057	1059	HR
O	1059	1060	)
O	1060	1061	.

O	1062	1064	We
O	1065	1069	used
O	1070	1073	the
O	1074	1082	landmark
O	1083	1089	method
O	1090	1092	to
O	1093	1102	calculate
O	1103	1111	residual
O	1112	1113	5
O	1113	1114	-
O	1114	1118	year
O	1119	1127	survival
O	1128	1133	rates
O	1133	1134	.

O	1135	1139	When
O	1140	1149	comparing
O	1150	1155	CIOFF
O	1156	1161	women
O	1162	1166	with
O	1167	1177	definitely
O	1178	1192	postmenopausal
O	1193	1198	women
O	1198	1199	,
O	1200	1203	the
O	1204	1212	survival
O	1213	1216	was
O	1217	1220	not
O	1221	1230	different
O	1230	1231	.

O	1232	1237	Among
O	1238	1243	CIOFF
O	1244	1249	women
O	1250	1254	with
O	1255	1264	available
O	1265	1267	E2
O	1268	1274	follow
O	1274	1275	-
O	1275	1277	up
O	1278	1284	values
O	1285	1286	(
O	1286	1287	n
O	1288	1289	=
O	1290	1293	329
O	1293	1294	)
O	1294	1295	,
B-outcome	1296	1308	experiencing
I-outcome	1309	1312	OFR
O	1313	1314	(
O	1314	1315	n
O	1316	1317	=
B-iv-bin-abs	1318	1320	39
O	1320	1321	)
O	1322	1325	had
O	1326	1328	an
O	1329	1340	unfavorable
O	1341	1347	impact
O	1348	1350	on
B-outcome	1351	1358	distant
I-outcome	1359	1369	recurrence
I-outcome	1369	1370	-
I-outcome	1370	1374	free
I-outcome	1375	1383	survival
O	1384	1385	(
O	1385	1387	HR
O	1388	1389	2
O	1389	1390	.
O	1390	1392	27
O	1393	1394	[
O	1394	1396	95
O	1396	1397	%
O	1398	1408	confidence
O	1409	1417	interval
O	1418	1419	[
O	1419	1421	CI
O	1421	1422	]
O	1423	1424	0
O	1424	1425	.
O	1425	1427	98
O	1427	1428	-
O	1428	1429	5
O	1429	1430	.
O	1430	1432	25
O	1432	1433	;
O	1434	1435	p
O	1436	1437	=
O	1438	1439	0
O	1439	1440	.
O	1440	1442	05
O	1442	1443	]
O	1444	1447	and
B-outcome	1448	1455	overall
I-outcome	1456	1464	survival
O	1465	1466	(
O	1466	1468	HR
O	1469	1470	2
O	1470	1471	.
O	1471	1473	61
O	1474	1475	[
O	1475	1477	95
O	1477	1478	%
O	1479	1481	CI
O	1482	1483	1
O	1483	1484	.
O	1484	1486	11
O	1486	1487	-
O	1487	1488	6
O	1488	1489	.
O	1489	1491	13
O	1491	1492	;
O	1493	1494	p
O	1495	1496	=
O	1497	1498	0
O	1498	1499	.
O	1499	1501	03
O	1501	1502	]
O	1502	1503	)
O	1503	1504	.

O	1505	1510	After
O	1511	1520	adjusting
O	1521	1524	for
O	1525	1530	tumor
O	1531	1539	features
O	1539	1540	,
O	1541	1544	the
B-outcome	1545	1548	HRs
O	1549	1555	became
O	1556	1557	2
O	1557	1558	.
O	1558	1560	11
O	1561	1562	(
O	1562	1564	95
O	1564	1565	%
O	1566	1568	CI
O	1569	1570	0
O	1570	1571	.
O	1571	1573	89
O	1573	1574	-
O	1574	1575	5
O	1575	1576	.
O	1576	1578	02
O	1578	1579	;
O	1580	1581	p
O	1582	1583	=
O	1584	1585	0
O	1585	1586	.
O	1586	1588	09
O	1588	1589	)
O	1590	1593	and
O	1594	1595	2
O	1595	1596	.
O	1596	1598	24
O	1599	1600	(
O	1600	1602	95
O	1602	1603	%
O	1604	1606	CI
O	1607	1608	0
O	1608	1609	.
O	1609	1611	92
O	1611	1612	-
O	1612	1613	5
O	1613	1614	.
O	1614	1616	45
O	1616	1617	;
O	1618	1619	p
O	1620	1621	=
O	1622	1623	0
O	1623	1624	.
O	1624	1626	07
O	1626	1627	)
O	1627	1628	,
O	1629	1641	respectively
O	1641	1642	.

O	1643	1646	The
O	1647	1655	residual
B-outcome	1656	1657	5
I-outcome	1657	1658	-
I-outcome	1658	1662	year
I-outcome	1663	1667	rate
I-outcome	1668	1671	for
I-outcome	1672	1679	distant
I-outcome	1680	1690	recurrence
I-outcome	1690	1691	-
I-outcome	1691	1695	free
I-outcome	1696	1704	survival
O	1705	1708	was
B-iv-bin-percent	1709	1711	76
I-iv-bin-percent	1711	1712	.
I-iv-bin-percent	1712	1713	9
I-iv-bin-percent	1713	1714	%
O	1715	1718	for
O	1719	1724	women
O	1725	1729	with
O	1730	1733	OFR
O	1734	1737	and
B-cv-bin-percent	1738	1740	92
I-cv-bin-percent	1740	1741	.
I-cv-bin-percent	1741	1742	1
I-cv-bin-percent	1742	1743	%
O	1744	1747	for
O	1748	1753	women
O	1754	1761	without
O	1762	1765	OFR
O	1765	1766	,
O	1767	1770	and
O	1771	1774	for
B-outcome	1775	1776	5
I-outcome	1776	1777	-
I-outcome	1777	1781	year
I-outcome	1782	1789	overall
I-outcome	1790	1798	survival
B-iv-bin-percent	1799	1801	80
I-iv-bin-percent	1801	1802	.
I-iv-bin-percent	1802	1803	8
I-iv-bin-percent	1803	1804	%
O	1805	1808	and
B-cv-bin-percent	1809	1811	94
I-cv-bin-percent	1811	1812	.
I-cv-bin-percent	1812	1813	4
I-cv-bin-percent	1813	1814	%
O	1814	1815	,
O	1816	1828	respectively
O	1828	1829	.

O	1830	1835	Women
O	1836	1840	with
O	1841	1846	CIOFF
O	1847	1856	receiving
O	1857	1868	anastrozole
O	1869	1872	may
O	1873	1875	be
O	1876	1878	at
O	1879	1888	increased
O	1889	1893	risk
O	1894	1896	of
O	1897	1904	disease
O	1905	1915	recurrence
O	1916	1918	if
O	1919	1931	experiencing
O	1932	1935	OFR
O	1935	1936	.
